https://www.selleckchem.com/ph....armacological_epigen
The 5-year survival rate of patients who underwent DP and DP-CAR were 50.6% and 41.1%, respectively (median survival time, 65.9 vs 37.0 months). For all 134 patients, pretreatment serum CA19-9 levels (P0.001), adjuvant chemotherapy (P0.001), and lymph node status (P=0.035) were independent prognostic factors of overall survival by multivariate analysis. DP-CAR following neoadjuvant chemotherapy for patients with borderline resectable or locally advanced pancreatic body carcinoma may bring the same survival impact as D
Like
Comment
Share
